An important limitation of our study is that it is based on a single patient and may not be representative of anti-CD19 therapy associated lineage switch, highlighting the need for longitudinal tissue banking to enable a general understanding of lineage-switch leukemia. This evidence concerns the gene CD19 and leukemia.